Certified by Founder Lodge
Surveyor Capital
United States - Chicago, Illinois
INVESTOR
1 Disclosed Funding Rounds $100,000,000
18 Participating Investments
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
-
Website
https://www.citadel.com/what-we-do/equities/surveyor-capital/
- Contact
- Social Links
Surveyor Capital is a longstanding fundamental equities business at Citadel, established in 2008. Our sector-aligned investment teams conduct deep fundamental research, developing an independ
Company | Date | Round | Raised |
---|---|---|---|
Aardvark Therapeutics | May, 10 ,2024 | Series C | $85,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Marea Therapeutics | June, 20 ,2024 | Series A | $190,000,000 |
Boundless Bio | May, 17 ,2023 | Series C | $100,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Quanta Therapeutics | May, 23 ,2023 | Series D | $50,000,000 |
Outpace Bio | August, 02 ,2024 | Series B | $144,000,000 |
Mariana Oncology | September, 08 ,2023 | Series B | $175,000,000 |
Adcendo | November, 26 ,2024 | Series B | $135,000,000 |
Avalyn Pharma Inc. | September, 28 ,2023 | Series C | $175,000,000 |
Veradermics | December, 12 ,2024 | Series B | $75,000,000 |
Sudo Biosciences | December, 21 ,2023 | Series B | $116,000,000 |
Aardvark Therapeutics | May, 10 ,2024 | Series C | $85,000,000 |
Marea Therapeutics | June, 20 ,2024 | Series A | $190,000,000 |
Scorpion Therapeutics | July, 17 ,2024 | Series C | $150,000,000 |
Outpace Bio | August, 02 ,2024 | Series B | $144,000,000 |
Adcendo | November, 26 ,2024 | Series B | $135,000,000 |
Veradermics | December, 12 ,2024 | Series B | $75,000,000 |